Premium
Low dosage alpha‐interferon treatment in patients with advanced cutaneous T‐cell lymphoma
Author(s) -
Hagberg H.,
Juhlin L.,
Scheynius A.,
Tjernlund U.
Publication year - 1988
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1988.tb00793.x
Subject(s) - medicine , lymphoma , alpha interferon , cutaneous t cell lymphoma , mycosis fungoides , interferon , interferon alfa , alpha (finance) , complete remission , gastroenterology , chemotherapy , immunology , surgery , patient satisfaction , construct validity
Treatment with high dose (10–50 × 10 6 IU/m 2 three times a week) of alpha‐interferon (α‐IFN) has been shown to induce remissions in about 50% of patients with cutaneous T‐cell lymphoma. The optimal α‐IFN dose, however, is not known. 4 patients with advanced cutaneous T‐cell lymphoma were therefore treated with α‐IFN in low doses of 2–4 × 10 6 IU/m 2 three times a wk. 1 complete, 1 partial and 1 minor remission were observed. Skin biopsies before and during treatment were taken from 2 of the patients and showed improvement. Low doses of α‐IFN can thus induce remission in patients with cutaneous T‐cell lymphoma.